Quintiles Transnational Corp. (Nasdaq: QTRN) has appointed Ray Dawkins as director of medical and scientific services director at its North American Clinical Development Services unit.
Dawkins will provide medical consultation and therapeutic expertise as a member of the company’s Clinical Development Services project teams. Quintiles is headquartered in Research Triangle Park.
Most recently, Dawkins served as the principal investigator for all studies conducted at PPD Development’s Phase I clinic in RTP. Earlier, he served as international director for the ACE inhibitor quinapril in the cardiovascular group of Parke-Davis in Ann Arbor, MI. At Parke-Davis, Dawkins was responsible for conducting Phase IIIb and IV studies on quinapril worldwide.
Prior to that, Dawkins served as the medical director of Clinical Research International, a contract research organization also based in RTP. He also has served as the assistant director of clinical development at Glaxo, where he was responsible for Phase IV trials, publications and marketing interactions for the gastrointestinal and anti-infectives groups.
Dawkins received his medical degree from Duke University School of Medicine in Durham. He completed a residency in internal medicine at the University of Missouri Health Sciences Center in Columbia, MO, and spent 13 years in private practice in internal medicine.
“Ray brings to our group a broad-based knowledge of the pharmaceutical industry in cardiovascular medicine, gastrointestinal disorders and anti- infectives,” David Frakes, vice president of medical and scientific services, said in a statement. “He adds further depth and breadth to the experience of our North American Medical and Scientific Services team, which already has 18 physicians–.”